The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.
Maurenis Hernandez
No relevant relationships to disclose
Eduardo Rafael Santiesteban
No relevant relationships to disclose
Ramon Alberto Ortiz
No relevant relationships to disclose
Elia Neninger
No relevant relationships to disclose
Soraida Acosta
No relevant relationships to disclose
Yoana Flores
No relevant relationships to disclose
Rosa Maria Amador
No relevant relationships to disclose
Mayte Robaina
No relevant relationships to disclose
Ivis Mendoza
No relevant relationships to disclose
Pedro Pablo Guerra
No relevant relationships to disclose
Anet Valdes
No relevant relationships to disclose
Ana Maria Vazquez
No relevant relationships to disclose
Amparo Macias
No relevant relationships to disclose
Tania Crombet
No relevant relationships to disclose